Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
Huamao Mark Lin, Xiaoyun Pan, Peijie Hou, Hui Huang, Yanyu Wu, Kaili Ren, Mohammad Jahanzeb
Abstract
Treatment of patients with ALK + NSCLC with ceritinib or alectinib as post-crizotinib, second-line ALK inhibitor therapy represents a high economic burden. Healthcare costs and resource utilization were significantly higher for patients with ALK + NSCLC with BM versus no BM.
Topics & Concepts
CrizotinibCeritinibAnaplastic lymphoma kinaseMedicineAlectinibALK inhibitorInternal medicineLung cancerOncologyKRASAnaplastic large-cell lymphomaRetrospective cohort studyCancerLymphomaMalignant pleural effusionColorectal cancerLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies